Go Pro
NASDAQ:IRIX

IRIDEX (IRIX) Stock Price, News & Analysis

IRIDEX logo
$0.83 -0.01 (-1.08%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$0.84 +0.00 (+0.54%)
As of 08/7/2026 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About IRIDEX Stock (NASDAQ:IRIX)

Advanced

Key Stats

Today's Range
$0.83
$0.84
50-Day Range
$0.82
$1.19
52-Week Range
$0.80
$1.65
Volume
25,283 shs
Average Volume
57,273 shs
Market Capitalization
$14.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Hold

Company Overview

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration. In addition to laser systems, IRIDEX offers a range of laser probes, fibers and accessories that enable physicians to tailor treatments to individual patient needs and optimize clinical outcomes.

Since its founding in 1983, IRIDEX has expanded its global footprint, serving ophthalmic practices, surgical centers and hospitals in over 50 countries. Headquartered in Mountain View, California, the company maintains regional operations and distribution partnerships across North America, Europe, Asia-Pacific and Latin America. IRIDEX continues to invest in research and development to enhance its proprietary technologies and support new applications in retinal and glaucoma care.

IRIDEX’s management team is led by Thomas T. Weppelmann Jr., President and Chief Executive Officer, who has guided the company through multiple product launches and market expansions. Under his leadership, IRIDEX has built a reputation for delivering reliable, precision-engineered laser systems and fostering long-term collaborations with clinical partners. The company remains committed to advancing ophthalmic therapy through ongoing innovation and partnerships with academic institutions and key opinion leaders.

AI Generated. May Contain Errors.

IRIDEX Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

IRIX MarketRank™: 

IRIDEX scored higher than 27% of companies evaluated by MarketBeat, and ranked 778th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IRIDEX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    IRIDEX has a consensus price target of $3.00, representing about 261.2% upside from its current price of $0.83.

  • Amount of Analyst Coverage

    IRIDEX has only been the subject of 1 research reports in the past 90 days.

  • Read more about IRIDEX's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IRIDEX is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IRIDEX is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about IRIDEX's valuation and earnings.
  • Percentage of Shares Shorted

    0.23% of the float of IRIDEX has been sold short.
  • Short Interest Ratio / Days to Cover

    IRIDEX has a short interest ratio ("days to cover") of 1.17, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IRIDEX has recently increased by 20.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IRIDEX does not currently pay a dividend.

  • Dividend Growth

    IRIDEX does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for IRIDEX this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, IRIDEX insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    8.60% of the stock of IRIDEX is held by insiders.

  • Percentage Held by Institutions

    20.10% of the stock of IRIDEX is held by institutions.

  • Read more about IRIDEX's insider trading history.
Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRIX Stock News Headlines

The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
Iridex (IRIX) Q1 2026 Earnings Transcript
See More Headlines

IRIX Stock Analysis - Frequently Asked Questions

IRIDEX's stock was trading at $1.14 on January 1st, 2026. Since then, IRIX stock has decreased by 27.1% and is now trading at $0.8305.

IRIDEX Corporation (NASDAQ:IRIX) released its quarterly earnings data on Tuesday, May, 19th. The medical equipment provider reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. The medical equipment provider had revenue of $11.80 million for the quarter, compared to analysts' expectations of $11.91 million.
Read the conference call transcript
.

Top institutional shareholders of IRIDEX include Bank of New York Mellon Corp (0.15%). Insiders that own company stock include Patrick Mercer, William M Moore, Beverly A Huss and Romeo R Dizon.
View institutional ownership trends
.

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IRIDEX investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/19/2026
Today
8/08/2026
Next Earnings (Estimated)
8/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:IRIX
CIK
1006045
Employees
120
Year Founded
1989

Price Target and Rating

High Price Target
$3.00
Low Price Target
$3.00
Potential Upside/Downside
+261.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$4.44 million
Net Margins
-6.23%
Pretax Margin
-6.03%
Return on Equity
N/A
Return on Assets
-11.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.92
Quick Ratio
1.19

Sales & Book Value

Annual Sales
$52.67 million
Price / Sales
0.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.06) per share
Price / Book
-13.84

Miscellaneous

Outstanding Shares
17,410,000
Free Float
15,910,000
Market Cap
$14.46 million
Optionable
Optionable
Beta
0.66

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:IRIX) was last updated on 8/8/2026 by MarketBeat.com Staff.
From Our Partners